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ABSTRACT
Objectives: Given use of uterotonics for postpartum
haemorrhage and other obstetric indications, the
importance of potent uterotonics is indisputable. This
study evaluated access to and potency of injectable
uterotonics in Ghana.
Design: Study design involved research assistants
simulating clients to purchase oxytocin and
ergometrine from different sources. Drug potency was
measured via chemical assay by the Ghana Food and
Drugs Board.
Setting: The study was conducted in three contrasting
districts in Ghana.
Outcome measure: The per cent of active
pharmaceutical ingredient was measured to assess the
quality of oxytocin and ergometrine.
Results: 69 formal points of sale were visited, from
which 55 ergometrine ampoules and 46 oxytocin
ampoules were purchased. None of the ergometrine
ampoules were within British Pharmacopoeia
speciﬁcation for active ingredient, none were expired
and one showed 0% active ingredient, suggestive of
a counterfeit drug. Among oxytocin ampoules
purchased, only 11 (26%) were within British
Pharmacopoeia speciﬁcation for active ingredient and
two (4%) were expired. The median percentages of
active ingredients were 64% and 50% for oxytocin and
ergometrine, respectively.
Conclusions: The quality of injectable uterotonics in
three contrasting districts in Ghana is a serious
problem. Restrictions regarding the sale of
unregistered drugs, and of registered drugs from
unlicensed shops, are inadequately enforced. These
problems likely exist elsewhere but are not assessed,
as postmarketing drug quality surveillance is generally
restricted to well-funded disease-speciﬁc programmes
relying on antiretroviral, antimalarial and antibiotic
drugs. Maternal health programmes must adopt and
fund the same approach to drug quality as is standard
in programmes addressing infectious disease.
INTRODUCTION
The most commonly used uterotonic drugs
in poor countries are injectable oxytocin,
injectable ergometrine and misoprostol
tablets. Injectable methylergometrine,
injectable syntometrine and ergometrine
tablets are also used. Oxytocin, ergometrine
and misoprostol are included in the WHO
Model List of Essential Medicines.
1 Based on
existing data, the WHO considers oxytocin
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ARTICLE SUMMARY
Article focus
- The need for high-quality uterotonic drugs for the
prevention and treatment of maternal mortality
and morbidity in poor countries is indisputable.
- Best practice for long-term storage for all
injectable uterotonics is refrigeration, which is
a key logistical constraint for scale up of
postpartum haemorrhage reduction strategies
and is a general challenge for maternity services
without consistent electricity.
- The objectives of the study were to assess the
population’s access to uterotonic drugs and to
assess the chemical potency of ampoules of
oxytocin and ergometrine available to the
population.
Key messages
- Quality of uterotonics is likely a serious problem
in Ghana; 89% of all ampoules tested in this
study did not meet the speciﬁcations for active
ingredient. The low level of active ingredient in
these ampoules is not due to old drugs; only 2%
of these ampoules had expired.
- There is little enforcement of the restriction
against chemical shops selling uterotonics or of
the sale of unregistered uterotonics in these
districts.
- Inactive uterotonics are not restricted to the
private sector; uterotonics outside speciﬁcation
were purchased from private and public sources.
It is also clear that public and private sources
procure unregistered uterotonics.
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Open Access Researchthe drug of choice for postpartum haemorrhage
prevention and treatment where a skilled care giver is
available, safe injection practices are ensured and
refrigeration is feasible.
2 Oxytocin is also included in the
new WHO list of priority medicines for mothers and
children for prevention of postpartum haemorrhage.
3 As
uterotonics are also used for other obstetric indications
(induction, augmentation of labour), the importance of
access to potent uterotonics throughout the antepartum
and early postpartum periods is indisputable.
Given that postpartum haemorrhage is a leading direct
cause of maternal death in many poor countries, large-
scale efforts have focused on in-service clinical training
for postpartum haemorrhage prevention and treatment,
which requires uterotonic drugs. However, best practice
for long-term storage for all injectable uterotonics is
refrigeration, which is a key logistical constraint for scale
up of postpartum haemorrhage reduction strategies and
is a general challenge for maternity services without
consistent electricity.
In 1993, a WHO simulation study testing the stability
of injectable uterotonic drugs showed that oxytocin lost
no active ingredient after 12 months under refrigeration
(48Ce88C), lost 3%e7% active ingredient after
12 months at 218Ce258C, lost 9%e19% active ingredient
after 12 months at 308C and was unaffected by exposure
to light. Ergometrine was shown to be much less stable,
losing 5% of its active ingredient after 12 months at
48e88C when stored in the dark, losing more than 90%
of its active ingredient when stored for 12 months at
218e258C exposed to light.
4
Few other studies were identiﬁed, which addressed
degradation of uterotonics resulting from environ-
mental exposure. Those that were identiﬁed are not
recent, and all focused only on oral and injectable
preparations of oxytocins: ergometrine, methylergome-
trine and oxytocin. Exact estimates of the shelf life of
oxytocin and ergometrine varied across the studies, but
in general, the results of these studies concurred with
the conclusion of the WHO simulation study that ergo-
metrine was much less stable under tropical conditions
than oxytocin, but that both posed public health
concerns in contexts without access to refrigeration.
5e8
No studies were identiﬁed, which addressed the potency
of misoprostol or the existence of counterfeit or
substandard (ie, drugs which at manufacture do not
meet the speciﬁcations reported by the manufacturer)
uterotonics.
In Ghana, there are approximately 1600 retail phar-
macies and 10000 chemical sellers, of which 7000 are
registered with the Pharmacy Council, the regulatory
body of the Ministry of Health tasked with ensuring the
quality, accessibility and equitable distribution of phar-
maceutical services, and the Association of Chemical
Sellers.
9 In Ghana, only those pharmacies with a License
A are legally authorised to sell uterotonic drugs.
The objectives of this study were (1) to assess the
population’s access to uterotonics with and without
prescription and (2) to assess potency of injectable
oxytocin and ergometrine from varying sources from
three contrasting districts in Ghana.
METHODS
The study design involved research assistants simulating
clients to purchase ampoules of oxytocin and ergome-
trine from different types of points of sale. In an effort to
design a representative sample of uterotonic points of
sale, one district was selected from each of the three
ecological regions of the country (coastal, forest and
savannah), which also differ on major socioeconomic
indicators.
In August 2010, a research assistant travelled
throughout the selected districts to compile a list
including all pharmacies and chemical shops. In addi-
tion, he was asked to compile information on informal
points of sale such as markets from which drugs might be
purchased from stationed sellers and mobile drug
peddlers. All efforts were made to compile an exhaustive
list, acknowledging that this is nearly impossible given
the informal and transient nature of some points of sale.
Upon the research assistant’s return to Accra, pharma-
cies and chemical shops in each district were consecu-
tively numbered, a random start number was selected
and points of sale were systematically selected with
a constant sampling interval until a sample of 25 points
of sale were identiﬁed in each district. In Yendi and
Kintampo North, all the chemical shops and pharmacies
identiﬁed during the listing exercise were selected for
a visit.
Two months later, a team of nine research assistants
simulated clients by visiting each selected point of sale
and requested drugs used by pregnant women to hasten
their delivery, adding that the drugs were needed for
his/her sister, who was soon due to deliver.
There was no verbal or written informed consent for
this study, as consent of the salesperson would have
undermined the simulation. If the salesperson requested
a prescription, the client provided a prescription for
ARTICLE SUMMARY
Strengths and limitations of this study
- An up-to-date listing of points of sale was compiled speciﬁcally
for this study; a sample of randomly selected sites was visited,
and in two of three districts, the selected points of sale
represented all the existing accessible chemical sellers and
pharmacies.
- The simulated client approach prevents possible bias in the
selection of ampoules to be sent for chemical testing.
- The number of points of sale selected for visit (25 per district)
was based on practical considerations and resulted in
a relatively small sample of ampoules available for chemical
testing.
- The sampling frame may not have been 100% exhaustive,
given the informal nature of some drug sellers. However, study
results were strikingly similar across three diverse districts,
and this is unlikely to result from sampling error.
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Uterotonic drug potency in Ghanaoxytocin and ergometrine, which was obtained from
a Ghana Health Service collaborator in Accra. This was
done for the following two reasons: (1) for human
subjects purposes to avoid putting the salesperson in the
position of being asked to sell drugs to a client without
a prescription even after the salesperson had asked for
one and (2) to ensure a sufﬁcient sample of ampoules
for chemical assay later. If the salesperson recommended
that the client go elsewhere, the research assistants
substituted the recommended location for the selected
site.
Purchased ampoules were placed in plastic bags with
coded information regarding the date of purchase,
expiry date of the ampoule, type of point of sale and
district name. These bags were placed in vaccine cold
chain carriers just after purchase and were placed in the
cold room or refrigerator of the district hospital as
quickly as possible and not later than the evening of the
day of purchase. Ampoules remained under refrigera-
tion in the district hospitals for 0e13 days before being
transported in the cold chain to Accra. In Accra, samples
were refrigerated for up to 1 week, after which all
samples were submitted to the Ghana Food and Drugs
Board. The Food and Drugs Board documented that all
ampoules were delivered under cold chain conditions.
Samples were refrigerated until analysis.
Samples were analysed according to the Finished
Pharmaceutical Product speciﬁcations of the British
Pharmacopoeia, 2010 edition, as all the samples had the
British Pharmacopoeia as their speciﬁcation. The US
Pharmacopeia chemical reference standards for ergo-
novine maleate (ergometrine maleate) RS and oxytocin
RS were used as standard comparators in the analysis: for
oxytocin, 46 oxytocin units per phial, USP Reference
Standard, Lot F1G134, Cat. No. 1491300; and for ergo-
novine maleate, 100 mg, USP Reference Standard, Cat.
No. 24000. The ampoules were tested without blinding
to product packaging, as information on the packaging
is required for testing. However, the manufacturer name
was not included among assay results, as required for
ethical approval of the study.
This study was approved by institutional review boards
at the Ghana Health Service in Accra, Ghana; PATH in
Seattle, Washington; and the Johns Hopkins Bloomberg
School of Public Health in Baltimore, Maryland.
RESULTS
Descriptive statistics for the study districts are provided
in table 1. Yendi district is located in the Northern
Region and is socioeconomically disadvantaged relative
to the other two districts. Socioeconomic indicators for
Kintampo North in Brong-Ahafo Region fall between
those of the Northern and Western Regions in which
Ahanta West District is located.
10
Sixty-nine visits to formal points of sale and 21 visits
to informal points of sale were made in total. Formal
points of sale included private pharmacies, chemical
shops and public health facility pharmacies. Informal
points of sale included market places, mobile peddlers
and herbal or home clinics. Although the original plan
was to restrict sampling to private points of sale, sales-
people occasionally either declined to sell uterotonic
drugs or did not have any to sell and recommended that
the client go to the nearby public health facility phar-
macy. Thus, as described in table 2, 10% of the 69
commercial points of sale visited were public health
facility pharmacies. Eighty-three per cent of visits to
formal points of sale were to chemical shops, with only
7% to private pharmacies. In Kintampo North and
Yendi districts, all chemical shops identiﬁed during the
August listing exercise were visited except for twodone
due to inaccessible roads and one which was closed
for the duration of ﬁeldwork. In Ahanta West, research
assistants went to pharmacies across district lines at
the recommendation of a salesperson. Half of the
informal points of sale were mobile peddlers (11 of
21), followed by market places (8 of 21). The list of
informal points of sale, which were visited, however, was
opportunistic.
A total of 101 ampoules were collected via the simu-
lated client exercise: 46 ampoules of oxytocin 10 IU and
55 ampoules of ergometrine 0.5 mg. Tables 3 and 4
present the per cent distribution of purchased ampoules
of oxytocin and ergometrine by district and by type of
point of sale, respectively. Only 15% of the ampoules
purchased were from Yendi district, with approximately
42% each purchased by the teams in Ahanta West and
Kintampo North. To note, there are no pharmacies in
Ahanta West District, the four pharmacies visited by the
simulated clients from Ahanta West were in a neigh-
bouring district to which they were referred. Approxi-
mately one third of the 101 ampoules were purchased
from chemical sellers, who in theory are not licensed to
sell uterotonic drugs. More than one in ﬁve ampoules
(22%) were purchased in public health facility pharma-
cies. In most cases, the simulated clients purchased one
ampoule each of ergometrine and oxytocin. At four
points of sale, simulated clients were sold ﬁve ampoules
Table 1 Regional socioeconomic indicators for study districts
Characteristic
Northern
Region (Yendi)
Brong-Ahafo
(Kintampo North)
Western Region
(Ahanta West)
% of reproductive aged women with no education 67.5 27.7 19
% of women using modern contraception 7.3 17.5 19.9
% of births assisted by a medically trained attendant 27.3 56.9 53.6
Source: Ghana Health Service, Ghana Statistical Service, Macro International.
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Uterotonic drug potency in Ghanaof both drugs, and at one site, they were sold 10 ergo-
metrine ampoules.
Products other than injectable uterotonics were
offered to and purchased by the simulated clients,
including ergometrine tablets, misoprostol and
Buscopan (used for labour induction in some settings).
None of these products were tested for active ingredi-
ents. No uterotonics were successfully purchased from
mobile peddlers, herbal/home clinics, or markets. A
variety of black or red powders or dark-coloured roots
were purchased from mobile peddlers in response to the
simulated client’s request for a product that would
hasten labour. Traditional preparations were not tested
for uterotonic properties.
Table 5 presents the distribution of the percentage of
active ingredient in the purchased ampoules of oxytocin
and ergometrine. Among the 46 oxytocin ampoules,
26% (11 ampoules) met British Pharmacopoeia speciﬁ-
cations, showing 90%e110% active ingredient. Only 4%
(two ampoules) of oxytocin ampoules had expired.
None of the 55 ergometrine ampoules met the British
Pharmacopoeia speciﬁcation, with a level of active
ingredient between 90% and 110%. Seventy-six per cent
of the ergometrine ampoules showed <60% active
ingredient. One ergometrine ampoule showed 0% active
ingredient and one showed 120% active ingredient.
None of the ergometrine ampoules had expired. The
median percentages of active ingredients were 64% and
50% for oxytocin and ergometrine, respectively.
Figures 1 and 2 illustrate the number of ampoules of
oxytocin and ergometrine by in-country registration
status of the product and by type of point of sale. None
of the oxytocin ampoules purchased were from a regis-
tered manufacturer of oxytocin. Eighteen of the
oxytocin samples (39%) were from manufacturers whose
registration status was pending, and 28 (61%) were from
unregistered manufacturers of oxytocin. Unregistered
oxytocin was purchased from chemical shops, private
pharmacies and public health facility pharmacies. All the
oxytocin ampoules from unregistered manufacturers
were outside speciﬁcation for active ingredient. One
third of the oxytocin ampoules from manufacturers with
pending registration status were outside speciﬁcation for
active ingredient (data not shown).
For ergometrine, 17 ampoules (31%) were from
registered manufacturers of ergometrine, 11 (20%) were
from manufacturers whose registration status was
pending and 27 (49%) were from unregistered manu-
facturers of ergometrine (including the ampoule with
0% active ingredient). As with oxytocin, unregistered
ergometrine was purchased from all types of points of
sale. All ergometrine ampoules were outside speciﬁca-
tion for active ingredient.
It was not possible to quantify results regarding the
need for a prescription to purchase uterotonics. In some
cases, salespeople made vague mention of the need for
a prescription, but never actually requested one, or they
asked for a prescription but never looked at it. Where
prescriptions were requested, all were given back to the
simulated client. In some cases where clients were
referred to a public health facility pharmacy, the
Table 2 Numbers and per cent distribution of the points of sale visited by simulated clients by district
District
Yendi Kintampo North Ahanta West Total Total %
Number of commercial points of sale
Private pharmacies 0 1 4* 5 7.3
Chemical shops/sellers 23 17 17 57 82.6
Public health facility pharmacies 6 1 0 7 10.1
Total 29 19 21 69 100
Number of informal points of sale
Markets 2 5 1 8 38.1
Home/herbal clinics 1 0 1 2 9.5
Mobile peddlers 4 3 4 11 52.4
Total 7 8 6 21 100
*All pharmacies were located outside the Ahanta West in a contiguous district.
Table 3 Per cent distribution of purchased oxytocin and
ergometrine ampoules by district
District Oxytocin (%) Ergometrine (%)
Yendi 15.2 14.5
Kintampo 30.4 51
Ahanta West 52.2 34.5
Missing 2.2 0
Total % (N) 100 (46) 100 (55)
Table 4 Per cent distribution of purchased oxytocin and
ergometrine ampoules by type of point of sale
Source of purchase Oxytocin (%) Ergometrine (%)
Private pharmacies 32.6 58.2
Chemical shops/sellers 39.1 23.6
Public health facility
pharmacies
26.1 18.2
Missing 2.2 0
Total % (N) 100 (46) 100 (55)
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nied the research assistant to the facility pharmacy. In
short, it appears that it was common but not universal
that the salesperson requested a prescription. The
research assistants also noted that salespeople often
assumed they were interested in uterotonic drugs for
abortion purposes, despite their story about a woman
who was soon to deliver.
DISCUSSION
Four messages resound from the analysis of this explor-
atory study: (1) quality of uterotonics is likely a serious
problem, at least in these districts in Ghana; 89% of all
ampoules tested in this study did not meet the speciﬁ-
cations for active ingredient; (2) the low level of active
ingredient in these ampoules is not due to old drugs;
only 2% of these ampoules had expired; (3) there is little
enforcement of the restriction against chemical shops
selling uterotonics or of the sale of unregistered utero-
tonics in these districts and (4) inactive uterotonics are
not restricted to the private sector; uterotonics outside
speciﬁcation were purchased from private and public
sources. It is also clear that public and private sources
procure unregistered uterotonics. It was not possible to
quantify results on the need for a prescription to
purchase uterotonics, though in many cases, the client
was at least vaguely asked for a prescription.
There are a number of strengths and limitations to this
study. Strengths include the fact that an up-to-date listing
of points of sale was compiled speciﬁcally for this study;
a sample of randomly selected sites was visited; and in
two of three districts, the selected points of sale repre-
sented all the existing accessible chemical sellers and
pharmacies. The simulated client approach would also
have prevented possible bias in the selection of
ampoules for testing. Limitations include the fact that
the sampling frame may not have been 100% exhaustive,
given the informal nature of some drug sellers, and that
the number of points of sale selected for visit (25 per
district) was based on practical considerations and
resulted in a relatively small sample of ampoules avail-
able for chemical testing. Study results were strikingly
similar across three diverse districts, however, and this is
unlikely to result from sampling error. Some misclassi-
ﬁcation between chemical sellers and pharmacies was
also possible, as shops were classiﬁed based on their
exterior signage. As simulated clients, the research
assistants could not ask questions regarding a shop’s
licenses or the qualiﬁcations of the salesperson.
Study results were shared with the Ghana Food and
Drugs Board and other interested parties and clearly
warrant in-depth investigation by both the Food and
Drugs Board and the Ghana Health Service. The difﬁ-
culties of the Ghana Food and Drugs Board in moni-
toring and addressing counterfeit and substandard
drugs have been highlighted in a recent private health
sector assessment by the World Bank.
11 A 2010 evalua-
tion of the efforts of the Medicines Transparency Alli-
ance (META) in Ghana includes among its 10
Table 5 Per cent distribution of the assay percentage of
active ingredient in purchased ampoules of oxytocin and
ergometrine
Assay
percentage
Oxytocin
10 IU (%)
Ergometrine
0.5 mg (%)
0 0 1.8
1e39 23.9 23.7
40e59 8.7 50.8
60e89 41.3 21.9
90e110 26.1 0
>110 0 1.8
Total % (N) 100 (46) 100 (55)
Median % 64 50.5
Per cent expired 4.3 (2) 0 (0)
Figure 1 Number of purchased ampoules of oxytocin by in-
country registration status of the product and by type of point of
sale.
Figure 2 Number of purchased ampoules of ergometrine by
in-country registration status of the product and by type of point
of sale.
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Uterotonic drug potency in Ghanarecommendations that each META Governing Council
meeting should include discussion of a speciﬁc
substantive drug-related issue and that these discussions
should be informed by a fact sheet of existing informa-
tion developed speciﬁcally for this purpose.
9 The results
of this study strongly support development of a fact sheet
on uterotonic drug quality by the META Governing
Council, as well as consideration of including one or
more uterotonic drugs on the list of tracer drugs in
Ghana. The common and accepted practice by public
health facilities of purchasing additional drugs on the
private market when centrally distributed stocks are low
requires closer monitoring by the Ghana Health Service
to prevent the purchase of unregistered drugs.
This study also raises a host of questions, which are not
speciﬁc to Ghana. For example, given the need for
additional data on uterotonic drug quality in poor
countries, which approaches to data collection and
sampling should be promoted and for which objectives?
Simulated clients were used in this study to ensure an
unbiased selection of ampoules for chemical testing and
to assess how well pharmacies follow existing regulations
requiring a prescription for the sale of uterotonic drugs.
An important consequence of using simulated clients,
however, is that it precludes data collection on why
ampoules were out of speciﬁcation for active ingredients.
In the absence of information on drug quality at
manufacture and packaging, and storage conditions
along the distribution chain, it is not possible to deter-
mine whether the cause is counterfeit, substandard or
degraded drugs. Although it is likely that at least one
reason for the low percentages of active ingredients is
unrefrigerated storage (for both oxytocin and ergome-
trine) and/or exposure to light (for ergometrine), one
does not know at which points along the distribution
chain this may have occurred. These limitations should
be seriously considered when deciding on study design.
Finally, the study also raises the question of which
uterotonic drugs should be tested. In this study, it was
considered unnecessary to test misoprostol. However,
given the rapid expansion of the availability of and
demand for misoprostol, particularly in South and
Southeast Asia,
12 counterfeit misoprostol is likely to
become a problem and should be considered for inclu-
sion in future studies.
The results of this study are sufﬁcient to raise serious
concerns regarding the quality of oxytocin and ergo-
metrine, particularly at the peripheral level in Ghana,
and potentially in other low-income countries. While
efforts to reduce maternal mortality have focused on
training health workers to prevent and treat postpartum
haemorrhage, these efforts and resources are under-
mined if health workers do not have access to high-
quality uterotonics. These results suggest that any
focused postpartum haemorrhage reduction strategy
also requires ongoing surveillance of uterotonic drugs,
enforcement of drug registration and pharmaceutical
licensing regulations, and increased attention to drug
storage and procurement. Postmarketing surveillance of
drug quality in low-income countries is often restricted
to disease-speciﬁc well-ﬁnanced health programmes
such as those that rely on antiretrovirals, antibiotics and
antimalarial drugs. Maternal health programmes must
adopt and fund the same approach to drug quality as is
standard in programmes addressing infectious disease.
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